

## Bibliografía recomendada

1. Alvarez, S., Herrero, C., Bru, E. and Perdigon G. 2001 Effect of *Lactobacillus casei* and yogurt administration on prevention of *Pseudomonas aeruginosa* infection in young mice. J. Food Prot. 64(11):1768-1774.
2. Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, Basbarrini G, and Gasbarrini A. 2001. The effect of oral administration of *Lactobacillus* GG on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. Aliment Pharmacol Ther Feb; 15(2):163-169.
3. Bezkorovainy, A. 2001. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 73:399S-405S.
4. Brady, L.J., Gallea, D.D., and Busta, F.F. 2000. The role of probiotic cultures in the prevention of colon cancer. J. Nutr. 130:410S-414S.
5. Cats, A., Kuipers, E.J. Bosschaert, M.A., Pot, R.G., Vanderbroucke-Grauls, C.M., Kesters, J.G. 2003. Effect of frequent consumption of a *Lactobacillus casei* containing milk drink in *helicobacter pylori*-colonized subjects. Aliment. Pharmacol. Ther. 17(3):429-435.
6. Charteres, W.P., P.M. Kelly, L. Morelli, and K. Collins. 1998. Ingredient selection criteria for probiotic micro-organisms in functional dairy foods. Int. J. Dairy Technol. 51:123-136.
7. Chateau, N., A. M. Deschamps, and A. Hadj Sassi. 1994. Heterogeneity of bile salts resistance in the *Lactobacillus* isolates of a probiotics. Lett. Appl. Microbiol. 18:42-44.
8. Consignado, G.O., Peña, A.C., and Jacalne A.V., 1993. In vitro study on the antibacterial activity of *Lactobacillus casei* (commercial yakult drink) against four diarrhea-causing organisms. Phil J. Microbiol Infect Dis. (22) 2.
9. Council For Agricultural Science and Technology (CAST) 2007. Probiotics: their potential to impact human health. Issue Paper 36: 1-20.
10. De Vrese, M., Stegelmann, A., Richter, B., Fenselan, S., Lane, Ch., and Schrezenmeir J., 2001. Probiotics – compensation for lactase insufficiency. Am. J. Clin. Nutr. 73(suppl)421-429.
11. Drouin, E. 1999. *Helicobacter pylori*: novel therapies. Can. J. Gastroenterol. 13:581-3.
12. Dunne, C. Mahony, L.O., Murphy, L., Thornton G., Morrissey, D., Halloran, S.O. Feeney, M., Flynn, S., Fitzgerald, G., Daly, C., Kiely, B., Sullivan, G.C., Shanahan F., and Collins K. 2001. *In vitro* selection criteria for probiotic bacteria of human origin: correlation with *in vivo* finding. Am J Clin Nutr. 73 (suppl) 386S-92S.
13. Ellen, S.M. 2000. Considerations for use of probiotic bacteria to modulate human health. J. Nutr. 130:384S-390S.

14. Fukuda, M; et al. 2002. Prebiotic Treatment of experimental colitis with: A comparison with probiotic or antibiotic Treatment. *Int. J. Mol Med.* Jan; 9 (1):65-70.
15. Food and Agriculture Organization of the United Nations (FAO) 2002. Guidelines for evaluation of probiotics in food. <ftp://ftp.fao.org/es/esn/food/wgreport2.pdf>.
16. Gill, H.S., and Guarner, F.2003. Probiotics and health: a clinic perspective. *Postgrad. Med J.* 80:516-526.
17. Guerrero A. M. L., Ruíz , P y S. G. 2000. El papel de los probióticos en la prevención y tratamiento de las infecciones gastrointestinales. *Memorias 2º Simposio Mexicano de Probióticos*, Guadalajara, Jalisco, México.
18. Hekmat Sh, and Koba L. 2006. Fermented dairy products: Knowledge and consumption. *J. of Dietetic Practice and Research.* 67(4):199-201
19. Heller, K.J. 2001. Probiotic bacteria in fermented foods: product characteristics and started organisms. *Am J Clin Nutr.* 73(suppl) : 374S-3749S.
20. International Scientific Association for Probiotics and Prebiotics (ISAPP) 2009. Clarification of the definition of probiotics. <http://www.isapp.net>.
21. Ishibashi, N., and Yamazaki, S. 2001. Probiotics and safety. *Am J Clin Nutr.* 73 (suppl): 465S-467S.
22. Isolauri, E., Sütas, Y., Kankaanpää P., Arvilommi H., and Salminen S.2001. probiotics: effects on inmunity. *Am J Clin Nutr.* 73 (suppl) 444-450.
23. Kim SH, Yang SJ, Koo HC, Bae WK, Kim JY, Park JH, Baek YJ, and Park YH. 2001 Inhibitory activity of *Bifidobacterium longum* HY8001 against Vero cytotoxin of *Escherichia coli* O157:H7. *J. Food Prot.* Nov ; 64(11)1667-1673.
24. Klaenhammer, T.R., Kullen, M.J. 1999. Selection and design of probiotics. *Int. J. food Microbiol.*50:45-57.
25. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunit HF. 2003. Probiotic beverage containing *Lactobacillus casei* Shirota improves gastrointestinal symptoms in patients with chronic constipationa. *Can J Gastroenterol.* 17:(x).
26. Lee, Y.K., Puong, K. Y., Ouwehand, A. C., and Salminen S. 2002. Displacement of bacterial pathogenes from mucus and caco-2 cell surface by lactobacilli. *J Med. Microbiol.* 52,925-930.
27. Majamaa H, Isolauri E. 1997. Probiotics: a novel approach in the management of food allergy. *J. Allergy Clin Immunol.* 99:179-185.
28. Mariano García-Garibay. 2000. Probióticos. 2º Simposio Mexicano de Probióticos. Pp. 57-65. Guadalajara, Jalisco, México.
29. Nagao, F., Nakayama, M., Muto, T., and Okumura K. 2000. Effects of a fermented milk drink containing *Lactobacillus casei* strain Shirota on the immune system in healthy human subjects. *Biosci Biotechnol Biochem.* 64(12) 2706-2708.

30. Reuter, G. 2001. The *Lactobacillus* and *Bifidobacterium* microflora of the human intestine: composition and secession. *Curr Issues. Intest. Microbiol.* 2 (2):43:53.
31. Sahagun FE, López PS, Ramírez JJ, García BS, Peregrina GR, García de Alba GJ. 2007. Erradicación de *Helicobacter pylori*: Esquema triple tradicional versus mismo esquema más probiótico. *Cirugía y Cirujanos* [en línea] 2007, 75 (septiembre-octubre). Disponible en: <http://redalyc.uaemex.mx/redalyc/src/inicio/ArtPdfRed.jsp?iCve=66275503>.
32. Sanders ME. 2009. How do we know when something called “Probiotic” is really a probiotic? A Guideline for consumers and health care professionals. *Functional Food Reviews* 1: 1(spring) 3-12.
33. Sgouras, D., Maragkoudakis, P., Petraki, K., Martinez-Gonzalez B., Eriotou. E., Michopoulos, S., Kalantzopoulos, G., Tsakalidou, E., and Mentis A. 2004. In vitro and in vivo inhibition of *Helicobacter pylori* by *Lactobacillus casei* strain Shirota. *Appl Environ Microbiol.* 70(1):518-526.
34. Sheil, B., McCarthy, J., O’Mahony, L., Bennett, M.W., Ryan, P., Fitzgibbon, J.J., Kiely, B., Collins, J.K., Shanahan, F. 2004. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis an arthritis. *Gut.* 53:694-700.
35. Shida, K., Takahashi, R., Iwadate E., TakamizawaK., Yasui H., Sato, T., Habu, S., Hachimura, S., and Kaminogawa S. 2002. *Lactobacillus casei* strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. *Clin. Exp. Allergy* 32:563-570.
36. Tanaka Ryuichiro. 1999. Health Promotion Effects of *Lactobacillus casei* strain Shirota. *En Lactobacillus casei* strain Shirota-Intestinal Flora and Human Health- Ed. Yakult Central Institute for Microbiological Research. Tokio, Japón.
37. Torres Vitela M. R. y col. 1999. Resistencia de la cepa *Lactobacillus casei Shirota* al efecto de algunos componentes del jugo gástrico. *Memorias.* 1<sup>er</sup> Congreso Internacional Sobre Inocuidad de Alimentos. Pp. 43. 5 y 6 de noviembre de 1999.
38. Torres Vitela M. R. y col. 2000. Antagonismo de *Lactobacillus casei* Shirota sobre *Escherichia coli* O157:H7. *Memorias.* 2<sup>o</sup> Congreso Internacional Sobre Inocuidad de Alimentos. Pp. 43. 7 y 8 de noviembre de 2000.
39. Torres-Vitela M. R. y col. 2001. Antagonismo de *Lactobacillus casei* Shirota sobre *Salmonella enteritidis* Y *Listeria monocytogenes*. *Memorias.* 3<sup>er</sup> Congreso Internacional Sobre Inocuidad de Alimentos. Pp. 75. 9 y 10 de noviembre de 2001.
40. Tuomola, E., Crittenden, R., Playne, M., Isolauri, E., and Salminen S. 2001. Quality assurance criteria for probiotic bacteria. *Am J Clin Nutr.* 73 (suppl):393S- 398S.
41. Vandenplas, Y., Ramirez, M.J., Castañeda, G. C., 2002. Consenso sobre probióticos, agentes bioterapéuticos en el manejo de las diarreas.

Microorganismos en los alimentos, suplementos alimenticios y medicamentos. Acta Pediatr. Méx. 23 (4) 243- 9

42. Waard, R., Claassen, E., Bokken, M. A. C. G., Buiting, B., Garsen, J., and Vos, J.G. 2003. Enhanced Immunological Memory Responses to *Listeria monocytogenes* in Rodents, as Measured by Delayed-Type Hypersensitivity (DTH), Adoptive Transfer of DTH, and Protective Immunity, following *Lactobacillus casei* Shirota Ingestion. Clin. Diag. Lab. Immun. 10(1):59-65.
43. World Gastroenterology Organization, 2008. Practice guidelines probiotics and prebiotics. WGO: 1-22